CYAN.OQ
Latest Trade
2.59USDChange
0.00(0.00%)Volume
17Today's Range
-
2.5952 Week Range
-
4.09As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 2.59 |
|---|---|
Open | 2.59 |
Volume | 17 |
3M AVG Volume | 0.05 |
Today's High | 2.59 |
Today's Low | 2.59 |
52 Week High | 4.09 |
52 Week Low | 2.01 |
Shares Out (MIL) | 5.91 |
Market Cap (MIL) | 14.80 |
Forward P/E | -- |
Dividend (Yield %) | -- |
Cyanotech Reports Q1 Loss Per Share $0.02
Cyanotech Reports Q4 Loss Per Share Of $0.25
Cyanotech Corp Says On April 22, Mawae Morton Resigned As CEO Of Co And Its Subsidiary
Cyanotech Corporation is engaged in the production of natural products derived from microalgae for the nutritional supplements market. The Company's products include Hawaiian Spirulina Pacifica and Hawaiian BioAstin. Hawaiian Spirulina Pacifica is a dietary supplement used for extra energy, a strengthened immune system, cardiovascular benefits and as a source of antioxidant carotenoids. Hawaiian BioAstin is a dietary antioxidant shown to support and maintain the body's natural inflammatory response, to enhance skin, and to support eye and joint health. The Company cultivates over two microalgal species from which its product lines, natural astaxanthin products and spirulina products, are derived. The Company produces its algae in Hawaii and manufactures the finished products in Hawaii and California.
Industry
Biotechnology & Drugs
Executive Leadership
Michael A. Davis
Independent Chairman of the Board
Gerald R. Cysewski
President, Vice Chairman of the Board, Chief Scientific Officer
Brian Brett Orlopp
Chief Financial Officer, Vice President of Finance and Administration, Secretary
Glenn D. Jensen
Vice President - Manufacturing and Infrastructure
Jennifer M. Johansen
Vice President - Quality & Regulatory Affairs
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 0.48 |
Price To Book (MRQ) | 0.98 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 61.42 |
LT Debt To Equity (MRQ) | 43.09 |
Return on Investment (TTM) | -10.22 |
Return on Equity (TTM) | -7.79 |
* UNDERTAKEN RE-INOCULATION OF SPIRULINA PONDS WHICH CO BELIEVE WILL ALLOW TO CORRECT NUTRIENT LEVELS & STABILIZE PRODUCTION
* CYANOTECH REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER OF FISCAL YEAR 2018
* CYANOTECH NAMES MAWAE MORTON AS CHIEF EXECUTIVE OFFICER AND A MEMBER OF THE BOARD OF DIRECTORS
* Cyanotech reports financial results for the second quarter of fiscal year 2018
* Cyanotech Corp - on July 14, co named Mawae Morton its president - SEC filing
* Cyanotech - co and Brent Bailey, former CEO, entered into settlement agreement resolving disputes with respect to separation agreement dated March 31, 2016
* Says on Feb 13, Meridian OHC Partners filed an amended complaint in which Co is not named as a defendant
* Cyanotech reports financial results for the third quarter and first nine months of fiscal year 2017
* Cyanotech reports financial results for the second quarter and first six months of fiscal year 2017
* Cyanotech names Nancy Katz as a director Source text for Eikon: Further company coverage:
* Meridian OHC Partners LP reports 13.3 percent stake in cyanotech corp as of oct. 18 - SEC Filing Source text (http://bit.ly/2dpgUD2) Further company coverage:
* Meridian OHC Partners LP reports 13.3 percent stake in Cyanotech Corp as of Oct. 6 - SEC filing Source text (http://bit.ly/2dVm2Aw) Further company coverage:
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.